Surgery is the only curative option for Stage I/II pancreatic cancer, nonetheless most patients will recur after surgery and die of their disease. To identify novel opportunities for management of recurrent pancreatic cancer we performed whole exome or targeted sequencing of 10 resected primary cancers and matched intrapancreatic recurrences or distant metastases. We identified that adjuvant or first-line platinum therapy corresponds to an increased mutational burden of recurrent disease. Recurrent disease is enriched for mutations that activate Mapk/Erk and PI3K/AKT signaling and develops from a monophyletic or polyphyletic origin. Treatment induced genetic bottlenecks lead to a modified genetic landscape and subclonal heterogeneity for driver gene alterations in part due to intermetastatic seeding. In one patient what was believed to be recurrent disease was an independent (second) primary tumor. These findings advocate for combination therapies with immunotherapy and routine post-treatment sampling as a component of management of recurrent pancreatic cancer.
Introduction
Pancreatic ductal adenocarcinoma (PDA) is currently the 3th leading cause of cancer death in the United States and is projected to become the 2nd cause of cancer death within five years (1, 2) . Several reasons account for these statistics, including an inability to diagnose the disease when at a curative stage, late presentation and modest impact of current best available therapies (3) . There is a limited understanding of the genetics of recurrent disease which limits targeted therapy opportunities or informed design of clinical trials.
Approximately 10-15% of newly diagnosed PDA patients are diagnosed with early-stage disease (Stage I or II). For these patients, surgical resection followed by adjuvant therapy is the only option for cure (3) . While long term survival following resection of PDA has been reported (4) (5) (6) , the majority of patients who undergo resection will recur locally or at distant sites and die of their disease within five years. Several factors have been shown to have predictive or prognostic value for disease free or overall survival in resected PDA patients, including a high ratio of involved to total resected lymph nodes, larger tumor size, high tumor grade, the presence of vascular and perineural invasion, or variably positive margins (7) (8) (9) . Venous invasion is very common in pancreatic cancer and may contribute to the aggressiveness of this disease (10) . Molecular features of PDA have also been attributed to worse outcome after surgery. For example, patients with co-incident TP53 and SMAD4 alterations have shorter disease-free survival than patients whose tumors do not have these genetic alterations (11) (12) (13) .
Alternatively, the presence of a basal expression signature (14) (15) (16) , paucity of an immune signature (17) or microbial dysbiosis (18) have also been associated with worse overall survival.
Ultimately the extent to which recurrent PDA has genetic features of clinical significance or potential actionability is unknown. To address this question and to improve our understanding of recurrent PDA we performed whole exome and/or targeted sequencing of 10 primary PDAs, matched local (pancreatic resection bed) recurrences and multiple anatomically diverse metastases. We identified that pancreatic cancer recurrences following surgery have an increased mutational burden, distinct subclonal origins and in some instances are characterized by somatic mutations with potential implications for clinical management.
Results
We screened a collection of more than 160 PDA research autopsies to identify patients for whom a sample of their original surgical pancreatic resection was available, who underwent adjuvant treatment after surgery, and who had histologically confirmed recurrent disease within the pancreatic remnant and one or more metastases to anatomically distinct sites such as the liver, lungs or peritoneum (Fig. 1A,B ). We identified nine such patients for study (Table   S1 ). An additional patient was included that did not have metastatic disease at autopsy but did have an aggressive local recurrence with multiple geographically distinct samples of this mass available for profiling. One normal tissue sample from each patient was also used to distinguish somatic from germline variants (Table S2 ).
All samples were analyzed by whole exome sequencing (WES) to a median of 330x coverage (range 135-652x)(see Methods, Table S3 ). To supplement the breadth of WES sequencing in these samples, we also performed concurrent deep sequencing using a targeted sequencing panel to ensure greater sensitivity for mutations and DNA copy number alterations in 410 cancer associated genes (Table S4 ) (19) . We identified 4864 total somatic single nucleotide variants (SNVs) and small insertions or deletions (indels) with a median of 57 per sample (range 17-203; Fig. 1C , Table S5 ). We found no evidence of microsatellite instability in these 10 patients, nor were germline or somatic mutations identified in recognized MSI-related or other DNA damage repair genes (20) .
To better understand the patterns of mutation accumulation in primary versus recurrent disease, we performed mutational signatures analysis of all samples that underwent WES ( Fig.   1D ). Nine signature classes were identified in our cohort: (21) . A high prevalence of Signature 9 (POLN) was seen in at least one sample in seven of eight patients. This signature is associated with somatic hypermutation by polymerase h, a DNA polymerase that plays a role in DNA repair by translesion synthesis (22) .
As previously reported, we also identified subsets of patients with an abundance of signatures with unknown etiology such as signatures 8 and 17 (17) . One patient (PAM41) had a remarkable abundance of mutations characteristic of signature 23, a rare type of signature of unknown etiology (21) . A comparison of the prevalence of each of these nine signatures in primaries to recurrent tumors revealed that a statistically different distribution in treated disease (two-sided c2-squared test, p<0.0001, Fig. 1E ). Comparisons of the prevalence of each signature class specifically in post-treatment recurrent disease versus treatment naïve primary carcinomas revealed a significant increase in the double strand break repair signature (median 16 somatic mutations per primary versus 92 in recurrent disease, Mann-Whitney U test, p<0.0001). Four patients received a platinum agent as part of their adjuvant or first line therapy for recurrent disease (Table S1 ), thus we determined the extent that this signature was enriched in these patients compared to those who received other regimens. Comparison of these two groups revealed that patients who did not receive a platinum agent had a modest yet significant increase in their recurrent disease with respect to the double strand break repair signature (median 58 somatic mutations per primary versus 532 in recurrent disease, Mann-Whitney U test, p<0.002), and this signature was remarkably more prevalent in the recurrent disease of patients who received one or more platinum agents (median 84.5 somatic mutations per primary versus 1379 in recurrent disease, Mann-Whitney U test, p<0.0001) ( Fig. 1F ).
We next determined the somatic alterations in known cancer genes in each patient. We identified somatic mutations in known PDA driver genes predicted to have functionally deleterious effects such as those in KRAS, CDKN2A, TP53, SMAD4, and ARID1B (Table S6 and   S7 ). Collectively, the genetic features of the resected PDA samples (sample PT1 from each patient) were consistent with previous sequencing studies of these cancers (15) . By contrast, the genomic features of recurrent disease ( Fig. 2 , Table S6 ) were notable for somatic alterations in additional genes, some of which are predicted to or likely to activate Mapk/Erk signaling (G12V mutation in KRAS, I679Dfs*21 mutation in NF1, R111X mutation in PPP6C) (23, 24) , PI3K/Akt/MTOR signaling (D323H hotspot mutation in AKT1, E542K hotspot mutation in PIK3CA, homozygous deletion of STK11) (25) , or MYC/MAX regulated gene expression (Y1312X mutation in CHD8, W1004X mutation in MGA, X863_ splicing mutation in NOTCH1, up to 16-fold amplification of MYC) (26, 27) . Somatic alterations in genes predicted to affect chromatinmediated gene expression (up to 38-fold focal amplification of HIST1H3B, frameshift mutations in KMT2B, KMT2C, KMT2D, c.4471-1N>A splicing mutations in TRIP12) (28) (29) (30) , nuclear export (E571K hotspot mutation in XPO1) (31) and DNA damage repair (c.497-1N>A splicing mutation in ATM, F134V mutation in TP53) were also found (32, 33) . Recurrences from two patients contained copy number alterations of genes implicated in innate immunity signaling (PRKCI 38fold focal amplification, TRAF3 homozygous deletion) (34, 35) . We also noted that whole genome duplication (WGD) was present in one or more samples of recurrent disease in eight patients (36) . In only two of these eight patients was WGD detected in the primary tumor indicating gains in ploidy may be common during PDA progression. Collectively these data identify potential signaling and transcriptional pathways by which recurrent disease develops;
with some exceptions these alterations are mutually exclusive across PDAs.
We hypothesized that somatic alterations identified in recurrent PDA samples reflect the clonal expansion of pre-existent populations following selective pressure imposed by adjuvant therapy. Pairwise cancer cell fraction (CCF) plots generated for all patients confirmed the enrichment of one or more subclonal populations in the recurrent disease compared to the primary tumor ( Fig. 3A ). We specifically focused on the AKT1 D323H in PAM40, PIK3CA E542K in PAM39 and NOTCH1 X863_splice site mutation in PAM41 as they represent functionally relevant alterations and in theory may be clinically actionable (http://oncokb.org). The KRAS p.G12V mutation in PAM40 was also of interest given recent reports of subclonal KRAS mutations in PDA (15) . Droplet digital PCR confirmed that in all instances these mutations existed in the primary tumor at prevalence rates from 0.2-2%, below the level of detection of our WES ( Fig.3B-D) .
To understand the evolutionary origins of recurrent disease in each patient we inferred phylogenies based on high confidence mutations in each patient (Methods)(37). One patient who was clinically thought to have an intrapancreatic recurrence of the resected PDA after 18 months, but molecular analysis revealed a second (independent) primary PDA ( Fig. 4A ). For example, the resected primary tumor (PAM44PT1) had a KRAS p.G12R mutation and 80 private passenger mutations, whereas the "recurrence" samples from this patient (PAM44PT2-PT5)
shared 124 mutations not seen in the primary. These latter mutations included a KRAS p.G12D, a TP53 p.F134V and a 29 basepair frameshift deletion in KMT2D (Fig. 4B) . A CCF plot of the original primary (PAM44PT1) compared to the "recurrence" samples confirmed the mutual exclusivity of the somatic mutations in each lineage ( Fig. 4C ). Re-review of the histology of the first primary tumor and associated imaging studies did not suggest the presence of a cystic neoplasm. These findings are highly indicative of two independent primary tumors that arose from distinct precursors (38) .
In Recognizing the sample numbers are low for robust outcomes analysis, exploratory analysis indicates that patients with monophyletic recurrences had a longer disease-free but not overall survival ( Fig. 5H ,I). From phylogenetic analysis alone, the timing of dissemination to other organs cannot be readily resolved. However, utilizing mathematical modeling and previously measured metastasis doubling times (39), we found that the minimal time required to grow from one to a billion cells (roughly 1 cm 3 ) is 1.82 years, or 21.9 months (90% CI: 1.61 -2.05 years) (Methods). Since clinical metastases occurred much earlier than these required 1.82 years after surgery in all patients with distant disease (median metastasis free survival 11.0 months, range 6-18 months) (Table S1 ), at least one of the metastases must have been microscopically seeded before surgery consistent with prior estimates (40) . Patient PAM46 typified these dynamics as they had a grossly positive surgical margin and developed a radiographically evident locoregional recurrence, but no metastases, 17 months after surgery ( Fig. S1J-L) . Irrespective of origin, in all nine patients additional subclonal expansions occurred after dissemination, in some cases resulting in spatial heterogeneity for driver gene mutations among the different sites of recurrent disease ( Fig. 5 and Figs. S1,S2).
We next sought to understand the clonal origins of local recurrences, a major clinical issue for patients who undergo potentially curative resection (41) . We therefore inferred the migration patterns of recurring disease across spatially distinct sites in each patient (Methods).
These analyses indicated that the seeding patterns of recurrent disease were diverse, with potentially multiple patterns arising even in the same patient. Metastasis to metastasis seeding was evident in some patients, typified by PAM37 in whom an omental metastasis seeded three liver metastases ( Fig. 6A ), in PAM38 in whom a liver metastasis seeded a lung metastasis ( Fig.   6B ), and in PAM45 in whom a perirectal metastasis seeded two abdominal wall metastases ( Fig   6C) . Local recurrences can also be seeded by the primary tumor or by a metastasis. In PAM41 respectively. Analysis of PAM39 and PAM40 indicated that two or more seeding patterns were equally likely to have occurred for all sites analyzed and thus no dissemination events could be confidently inferred. Inter-metastatic seeding was inferred in patients with both monophyletic (PAM37, PAM38, PAM42) and polyphyletic (PAM41, PAM43, PAM45) recurrences collectively indicating that migration patterns are unrelated to phylecity of the recurrent disease. While we studied a small cohort, surgical margin status appeared to be unrelated to the origin of a local recurrence. For example, local recurrences seeded by the primary tumor were noted in patients with negative surgical margins (i.e. PAM41, Fig. 7A ) whereas local recurrences seeded by a metastasis were noted in patients with a positive surgical margin (i.e PAM38, Fig. 6B ).
Discussion
To date genomic studies of PDA have primarily relied on resections or biopsies of treatment naïve disease (14, 15, 42) . Herein, we demonstrate that study of post-treatment samples may have value in identifying putative therapeutic vulnerabilities in recurrent disease.
Of immediate clinical relevance is the finding of an increased tumor mutational burden in recurrent disease of patients treated with platinum agents, a finding that provides a rationale and context for the use of immunotherapy in the management of this disease (43) .
Furthermore, we also find that recurrent disease is enriched for hotspot mutations in genes associated with Mapk/Erk or PI3K/Akt signaling, some of which are potentially actionable(http://oncokb.org). Importantly, these targets are pre-existent and selected for during adjuvant treatment itself. While our sample size is sufficient for a robust gene discovery in advanced pancreatic cancer, we identified genes not commonly associated with the PDA landscape such as the nuclear exportin XPO1, the serine-threonine protein phosphatase PPP6C (24, 31) , or regulators of innate immunity (PRKCI, TRAF3) (34, 35) . These findings support the need for prospective and statistically robust efforts to sequence post-treatment PDA to better define the genes or pathways repeatedly targeted by somatic alteration. Genetic sequencing of post-treatment PDA is a critical step forward for real time molecularly informed management of recurrent disease.
Another important finding of this study is that it illustrates a taxonomy by which recurrent PDA may be stratified: monophyletic origin, polyphyletic origin or unique origin (i.e. synchronous/metachronous primaries). In all patients with bona fide recurrent PDA of mono-or polyphyletic origin, we find that systemic subclinical dissemination had already occurred at the time of surgery consistent with prior estimates (40) . Questions for future investigation thus relate to methods to identify mono-versus polyphyletic recurrences in real time, and the clinical significance of this finding in the context of ongoing or planned clinical trials. Finally, while second primary carcinomas of the pancreas have been reported, our finding of a metachronous primary PDA in one of 10 otherwise unselected patients with an intrapancreatic mass post resection suggest that this phenomenon may be more common than previously appreciated (44, 45) . Detailed and formal prospective studies of intrapancreatic masses in patients who have undergone prior resection for PDA will be required to more firmly understand the frequency of second primary tumors and the risk factors associated with their development as has been shown for invasive carcinomas arising in intraductal papillary mucinous neoplasms of the pancreas (46) .
Finally, we note that the genomic features of these patients, all of whom presented with Stage I/II disease and underwent surgery and therapy, are in stark contrast to those of untreated Stage IV PDA (47) . In untreated PDA the genetic features of both the primary and metastases are remarkably uniform, and the genetic heterogeneity seen appears due exclusively to passenger mutations. By contrast, Stage I/II disease is notable for subclonal heterogeneity for driver genes as reported in other tumor types (48, 49) . Treatment induced genetic bottlenecks that sculpt the genomic landscape of PDA, together with intermetastatic seeding, likely contribute to subclonal and inter-metastatic heterogeneity for driver gene alterations observed in recurrent disease. Thus, context appears key in the interpretation of heterogeneity in PDA.
In summary, we identify novel genetic features of PDA in the context of recurrent disease after surgical resection and treatment with potential clinical implications for use of immunotherapy and targeted therapies in disease management. In the event that therapeutically targetable gene alterations are validated in recurrent disease, and as more targeted therapies become available, post-treatment sampling is likely to contribute to identification of the mechanisms of resistance and early identification of resistant clones. (Table   S3 ). Paired-end sequencing data were aligned to the reference human genome (hg19) using BWA (50) . Read de-duplication, base quality recalibration, and multiple sequence realignment were performed using the Picard Suite and GATK (51, 52) . Point mutations and small insertions and deletions were detected with MuTect and HaplotypeCaller, respectively (53) . Genome-wide total and allele-specific DNA copy number was determined using the FACETS algorithm (54) .
Methods
For targeted sequencing of 410 cancer genes, barcoded libraries from patient-matched tumor and normal samples were captured and sequenced using methods previously reported in detail (19) . (Table S5 ). MSI status was inferred from the sequencing data using a clinically validated algorithm (56) , with MSI-H defined as an MSIsensor score ≥10. Copy number alterations and whole genome duplication were inferred by FACETs (54) .
Phylogenetic analysis. We applied Treeomics v1.6.0 to reconstruct the phylogenies of recurrent disease using high quality somatic variants identified by whole exome sequencing (37) .
Treeomics uses a Bayesian inference model to account for sequencing errors and low purity and employs Integer Linear Programming to infer a maximum likelihood tree. Mutational signatures. Mutational signatures were derived using the methods described by Alexandrov et al (21) . To enrich for the most abundant signatures we merged those with similar putative etiologies into a single group. Signature groups present in at least 20% abundance in at least one sample were included for additional study and statistical analysis. 
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indicates a statistically significant difference in distribution between the two groups (two-sided c2-squared test, p<0.0001). A statistically significant increase in mutations characteristic of the DNA damage repair signature are also present in recurrent disease (p<0.0001, Mann-Whitney U test_ F. Comparison of DNA damage repair signature in patients who did and did not receive a platinum agent as adjuvant or first line therapy. All comparisons by Mann-Whitney U test. Phylogenetic analysis of the relationships of the primary tumor to the local recurrence and liver metastases in patient PAM40. All recurrent disease is the result of clonal expansion of a single pre-existent subclone notable for an AKT1 and KRAS mutations (See Fig 2B) . The primary tumor (PT1) is the outgroup in the tree. A subclonal TRIP12 mutation is also seen in a single liver metastasis. B. Color code of sample origins in PAM40. C. Phylogenetic analysis of the relationships of the primary tumor to the local recurrence and liver metastases in patient PAM39. In this patient the recurrent disease is the result of more than one clonal expansion. The preexistent PIK3CA mutation has expanded in the lineage that gave rise to samples PT2 and PT9. D. Color code of sample origins in PAM39. E,F. Jaccard indices for each pairwise comparison in PAM40 (monophyletic recurrence) versus PAM39 (polyphyletic recurrence). G. Comparison of the average Jaccard index for primary tumors and their matched recurrences in 
